Measles vaccine: Past, present, and future

Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2016, Pages 133-140

  Zachariah, Philip ^a,b   Stockwell, Melissa S ^a,b,c  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD147 ANTIGEN; CD150 ANTIGEN; CD209 ANTIGEN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; LANGERIN; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; NUCLEOTIDE; PROTEIN C; RETINOL; RIBAVIRIN; STRUCTURAL PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRULENCE FACTOR; VIRUS PROTEIN V;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DISEASE ERADICATION; EPIDEMIC; GENE SEQUENCE; GENOTYPE; HEALTH CARE DELIVERY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LANGERHANS CELL; MEASLES VACCINATION; NEGATIVE-STRAND RNA VIRUS; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; VACCINATION; VIRUS ENVELOPE; VIRUS REPLICATION; GENETICS; HEALTH; IMMUNOLOGY; MEASLES; MEASLES VIRUS; PATHOLOGY; PHYSIOLOGY; POST EXPOSURE PROPHYLAXIS;

GLOBAL HEALTH; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; POST-EXPOSURE PROPHYLAXIS;

EID: 84956603346     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.606     Document Type: Review

References (74)

1. World Health Organization-Measles. http://htt.who.int/mediacentre/factsheets/fs286/en/. Accessed June 10, 2015.
2. Muscat M., Who gets measles in Europe? J Infect Dis. 2011;204 Suppl 1: S353-365.
3. Gastañaduy PA, Redd SB, Fiebelkorn AP, et al., Measles-United States, January 1-May 23, 2014. MMWR Morbid Mortal Wkly Rep. 2014; 63 (22): 496-499.
4. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K., Measles outbreak-California, December 2014-February 2015. MMWR Morbid Mortal Wkly Rep. 2015; 64 (6): 153-154.
5. Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS., Measles-United States, January 4-April 2, 2015. MMWR Morbid Mortal Wkly Rep. 2015; 64 (14): 373-376.
6. European Center for Disease Prevention and Control-Surveillance data. http://ecdc.europa.eu/en/healthtopics/measles/epidemiological-data/pages/annual-epidemiological-reports.aspx. Accessed June 13, 2015.
7. Moss WJ, Griffin DE., Measles. Lancet. 2012; 379 (9811): 153-164.
8. Hashiguchi T, Kajikawa M, Maita N, et al., Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci USA. 2007; 104 (49): 19535-19540.
9. World Health Organization. 2001. Nomenclature for describing the genetic characteristics of wild-type measles virus. Wkly Epidemiol Rec. 76: 249-251.
10. Centers for Disease Control-Genetic Analysis of Measles Viruses. http://www.cdc.gov/measles/lab-tools/genetic-analysis.html. Accessed June 18, 2015.
11. Yanagi Y, Takeda M, Ohno S., Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol. 2006;87(Pt 10): 2767-2779.
12. Dhiman N, Jacobson RM, Poland GA., Measles virus receptors: SLAM and CD46. Rev Med Virol. 2004; 14 (4): 217-229.
13. Watanabe A, Yoneda M, Ikeda F, Terao-Muto Y, Sato H, Kai C., CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J Virol. 2010; 84 (9): 4183-4193.
14. Avota E, Koethe S, Schneider-Schaulies S., Membrane dynamics and interactions in measles virus dendritic cell infections. Cell Microbiol. 2013; 15 (2): 161-169.
15. Lemon K, de Vries RD, Mesman AW, et al., Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog. 2011; 7 (1): e1001263.
16. Singh BK, Hornick AL, Krishnamurthy S, et al., The Nectin-4/Afadin protein complex and intercellular membrane pores contribute to rapid spread of measles virus in primary human airway epithelia. J Virol. 2015; 89 (14): 7089-7096.
17. De Jong JG, Winkler KC., Survival of measles virus in air. Nature. 1964; 201: 1054-1055.
18. AAP. Measles virus. In: Pickering L, Baker CJ, eds. AAP committee on infectious diseases, red book. American Academy of Pediatrics. 2012:489-499.
19. Maldonaldo YA., Rubeola virus (measles and subacute sclerosing panencephalitis). In Long S, Pickering L, Prober CG, eds. Principles and Practices of Pediatric Infectious Diseases. London: Churchill Livingstone; 2008:1120-1125.
20. Hussey GD, Klein M., A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med. 1990; 323 (3): 160-164.
21. Caulfield LE, de Onis M, Blössner M, Black RE., Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. Am J Clin Nutr. 2004; 80 (1): 193-198.
22. WHO/UNICEF/IVAGG Task Force. Vitamin A Supplements-A Guide to Their Use in The Treatment and Prevention of Vitamin A Deficiency and Xerophthalmia. Geneva: WHO; 1997.
23. American Academy of Pediatrics Committee on Infectious Diseases: Vitamin A treatment of measles. Pediatrics. 1993; 91 (5): 1014-1015.
24. Sudfeld CR, Navar AM, Halsey NA., Effectiveness of measles vaccination and vitamin A treatment. Int J Epidemiol. 2010;39 Suppl 1: i48-55.
25. Griffin DE., Measles virus-induced suppression of immune responses. Immunol Rev. 2010; 236: 176-189.
26. De Vries RD, McQuaid S, van Amerongen G, et al., Measles immune suppression: lessons from the macaque model. PLoS Pathog. 2012; 8 (8): e1002885.
27. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT., Vaccines. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015; 348 (6235): 694-699.
28. Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014;311(8):826-835.
29. Centers for Disease Control-Measles history. http://www.cdc.gov/measles/about/history.html. Accessed June 18, 2015.
30. Fulginiti VA, Eller JJ, Downie AW, Kempe CH., Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967;202(12):1075-1080.
31. Aldous IR, Kirman H, Butler N, Goffe AP, Laurence GD, Pollock TM., Vaccination against measles: Part III. Clinical trial in British children. BMJ. 1961;2:1250-1253.
32. Benson PF, Butler NR, Goffe AP, et al., Vaccination of infants with living attenuated measles vaccine (Edmonston strain) with and without gamma-globulin. BMJ. 1964;2:851-853.
33. Krugman S., Present status of measles and rubella immunization in the United States: A medical progress report. J Pediatr. 1977; 90 (1): 1-12.
34. World Health Organization-Biologicals-Measles. http://www.who.int/biologicals/vaccines/measles/en/. Accessed June 18, 2015.
35. Bankamp B, Takeda M, Zhang Y, Xu W, Rota PA., Genetic characterization of measles vaccine strains. J Infect Dis. 2011;204 Suppl 1:S533-S548.
36. Food and Drug Administration-Measles, Mumps and Rubella Vaccine. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123789.pdf. Accessed June 19, 2015.
37. Food and Drug Administration-Measles, mumps, rubella and varicella vaccine live. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123796.pdf.
38. Food and Drug Adminitration-Thiomersal in Vaccines. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm096228.htm#thi. Accessed June 19, 2015.
39. Arya SC, Agarwal N., Efficacy of measles vaccine interlinked with potency and storage. Acta Trop. 2004; 90: 223e5.
40. Nokes DJ, Swinton J., Vaccination in pulses: A strategy for global eradication of measles and polio? Trends Microbiol. 1997; 5 (1): 14-19.
41. Helfand RF, Kebede S, Gary HE Jr, Beyene H, Bellini WJ., Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol. 1999; 6 (2): 178-180.
42. Hayden GF., Measles vaccine failure. A survey of causes and means of prevention. Clin Pediatr (Phila). 1979; 18 (3):155-156,161-163,167.
43. Moss WJ, Scott S., WHO Immunological Basis for Immunization Series: Measles. Geneva: World Health Organization; 2009.
44. World Health Organization-Recommended routine immunizations for children. http://www.who.int/immunization/policy/Immunization-routine-table2.pdf. Accessed on June 19, 2015.
45. De Serres G, Boulianne N, Defay F, et al., Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis. 2012; 55 (3): 394-402.
46. American Academy of Pediatrics Committee on Infectious Diseases. Measles: reassessment of the current immunization policy. Pediatrics. 1989;84(6):1110-1113. Erratum in: Pediatrics. 1990; 85 (5): 714.
47. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics. 1998;101(1 Pt 1):129-133.
48. Vukshich Oster N, Harpaz R, Redd SB, Papania MJ. International importation of measles virus-United States, 1993-2001. J Infect Dis. 2004;189.
49. Papania MJ, Hinman AR, Katz SL, Orenstein WA, McCauley MM. Progress toward measles elimination-absence of measles as an endemic disease in the United States. J Infect Dis. 2004;189(Suppl 1).
50. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC., Secondary failure rates of measles vaccines: A metaanalysis of published studies. Pediatr Infect Dis J. 1996;15(1):62-66.
51. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H., Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up. J Infect Dis. 2008; 197 (7): 950-956.
52. Helfand RF, Kim DK, Gary HE, Jr, et al. Nonclassic measles infections in an immune population exposed to measles during a college bus trip. J Med Virol. 1998; 56 (4): 337-341.
53. Lievano FA, Papania MJ, Helfand RF, et al., Lack of evidence of measles virus shedding in people with inapparent measles virus infections. J Infect Dis. 2004;189 Suppl 1: S165-170.
54. Haralambieva IH, Ovsyannikova IG, O'Byrne M, Pankratz VS, Jacobson RM, Poland GA., A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine. 2011; 29 (27): 4485-4491.
55. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA., The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013; 12 (1): 57-70.
56. Measles in Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book). Atlanta, GA: Centers for Disease Control; 2015.
57. Klein NP, Fireman B, Yih WK, et al., Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010; 126 (1): e1-8.
58. Klein NP, Lewis E, Fireman B, et al., Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015; 135 (2): e321.
59. Rowhani-Rahbar A, Fireman B, Lewis E, et al., Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013; 167 (12): 1111-1117.
60. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B., Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001; 84 (3): 227-229.
61. Bitnun A, Shannon P, Durward A, et al., Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis. 1999; 29 (4): 855-861.
62. Institute of Medicine. Adverse effects of vaccines, evidence and causality. https://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx. Accessed June 19, 2015.
63. Scott P, Moss WJ, Gilani Z, Low N., Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis. 2011;204 Suppl 1: S164-178.
64. Premenko-Lanier M, Rota PA, Rhodes G, et al., DNA vaccination of infants in the presence of maternal antibody: A measles model in the primate. Virology. 2003; 307: 67-75.
65. Premenko-Lanier M, Rota PA, Rhodes GH, Bellini WJ, McChesney MB., Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis. 2004; 189: 2064-2071.
66. Low N, Bavdekar A, Jeyaseelan L, et al., A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med. 2015; 372 (16): 1519-1529.
67. Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR., A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015;pii:S0264-410X(15)00285-6.
68. Moss WJ, Strebel P., Biological feasibility of measles eradication. J Infect Dis. 2011;204 Suppl 1: S47-53.
69. Orenstein WA, Strebel PM, Hinman AR., Building an immunity fence against measles. J Infect Dis. 2007; 196 (10): 1433-1435.
70. De Quadros CA, Izurieta H, Carrasco P, Brana M, Tambini G., Progress toward measles eradication in the region of the Americas. J Infect Dis. 2003;187 Suppl 1: S102-110.
71. Measles and rubella initiative, a global partnership to stop measles and rubella. http://www.measlesrubellainitiative.org. Accessed June 19, 2015.
72. Lieu TA, Ray GT, Klein NP, Chung C, Kulldorff M., Geographic clusters in underimmunization and vaccine refusal. Pediatrics. 2015; 135 (2): 280-289.
73. Sugerman DE, Barskey AE, Delea MG, et al., Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics. 2010; 125 (4): 747-755.
74. Halsey NA, Salmon DA., Measles at Disneyland, a problem for all ages. Ann Intern Med. 2015; 162 (9): 655-656.